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In genetically susceptible C57BL/6 mice the LP-BM5 isolate of murine retroviruses causes profound splenomegaly,
lymphadenopathy, hypergammaglobulinemia, and an immunodeficiency syndrome bearing many similarities to the patholo-
gies seen in AIDS. Because of these similarities, which also include terminal B cell lymphoma formation, this syndrome has
been called murine AIDS or MAIDS. Prompted by previous reports showing that the onset of MAIDS is dependent on the
presence of both CD41 T and B cells, we have previously shown that anti-gp39/CD40 ligand mAb (anti-CD40L mAb) treatment
of LP-BM5-infected mice is effective in inhibiting the induction of MAIDS when a short course of anti-CD40L mAb treatment
was started on the same day as LP-BM5 administration. The success of anti-CD40L mAb therapy, as indicated by a much
reduced degree of splenomegaly, hypergammaglobulinemia, and mitogen and allogeneic CTL unresponsiveness, demon-
strated that CD40L/CD40 interactions were critical to the establishment of MAIDS. Here we extend these findings through
the use of delayed anti-CD40L mAb treatment of mice, beginning 3–4 weeks after LP-BM5 infection, by showing that
interruption of CD40L/CD40 interactions also interferes with the progression of MAIDS. About 60% of LP-BM5-preinfected
mice were affected by delayed anti-CD40L mAb treatment, with substantially reduced spleen weights and serum hypergam-
maglobulinemia and normal or greatly restored proliferative responses to Con A stimulation and CTL responses to allogeneic
stimulation. The other LP-BM5-infected mice that did not respond to anti-CD40L therapy were found to have made antibodies
to the anti-CD40L mAb. Thus, in a majority of mice anti-CD40L mAb therapy was very effective in interfering with MAIDS
pathogenesis well after the establishment of the virus infection and MAIDS symptomatology, indicating that CD40L/CD40
interactions are crucial to the maintenance and progression of the disease, as well as its initiation. © 1998 Academic Press
INTRODUCTION
LP-BM5, a murine retrovirus isolate, induces a murine
immunodeficiency syndrome in genetically susceptible
mice such as the C57BL/6 (B6) strain. This highly patho-
genic isolate contains a mixture of murine leukemia
retroviruses including ecotropic, recombinant mink cell
cytopathic focus-inducing, and replication-negative/de-
fective viruses, with the defective genome serving as the
proximal etiological agent of disease (Aziz et al., 1989;
Chattopadhyay et al., 1989; Hartley et al., 1989; Huang et
al., 1989; Mosier et al., 1985; Jolicoeur, 1991; Kubo et al.,
1996). Many of the described disease features of the
LP-BM5-induced syndrome are similar to those occur-
ring in human AIDS; hence, the designation murine AIDS
or MAIDS. Similarities include hypergammaglobulinemia
(hyper-Ig), splenomegaly, lymphadenopathy, depen-
dence on CD41 T cells for initiation of disease, severely
dampened T and B cell responses, increased suscepti-
bility to infection and death when exposed to normally
nonpathogenic microorganisms, and the development of
terminal B cell lymphomas (Huang et al., 1995; Buller et
al., 1987; Cerny et al., 1990; Klinken et al., 1988; Klinman
et al., 1989; Legrand et al., 1981; Morse et al., 1989, 1992;
Mosier et al., 1987; Pattengale et al., 1982; Yetter et al.,
1988).
The induction of MAIDS by LP-BM5 has been shown to
require the presence of both CD41 T and B cells (Cerny
et al., 1990; Yetter et al., 1988). CD41 T cell depletion
experiments have been shown to render genetically sus-
ceptible, LP-BM5-infected mice resistant to the develop-
ment of MAIDS (Yetter et al., 1988). In vivo depletion of
neonatal mice of B cells from birth by administration of
rabbit antibody to cell surface IgM has also caused
genetically susceptible mice to become resistant to
MAIDS induction following infection with LP-BM5 (Cerny
et al., 1990). In keeping with these findings, which sug-
gest a requirement for both B and T cells for the estab-
lishment of LP-BM5-induced MAIDS, CD41 T helper
cell–B cell interactions have been shown to be neces-
sary for the induction of the polyclonal B cell activation
and differentiation to hyper-Ig secretion that are charac-
teristics of MAIDS (Yetter et al., 1988). Results from a
study involving major histocompatibility complex class
II-negative mice as a source of B cells, with or without
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transferred CD41 cells, have suggested that Th cell
recognition of B cell class II presented antigen may be
necessary for the induction of MAIDS (Giese et al., 1994).
Because B cells have been shown to be the primary cell
type for expression of the defective retrovirus after LP-
BM5 infection (Huang et al., 1991; Kim et al., 1994), the
results obtained with the MHC class II-deficient mice are
consistent with the possibility that defective retrovirus-in-
fected B cells, presenting antigen in the context of MHC
class II, are important during MAIDS disease initiation.
Bearing in mind the possibility of requisite T and B cell
interactions for MAIDS induction by LP-BM5, we recently
investigated the role of gp39(CD40L)/CD40 interactions
in the establishment of MAIDS (Green et al., 1996).
CD40L, which has recently been designated CD154, has
been shown to be transiently expressed on activated T
cells, especially murine CD41 T cells, after stimulation
through the T cell receptor for antigen (Armitage et al.,
1992; Noelle et al., 1992). Once expressed, CD40L serves
as the ligand for CD40, a 50-kDa B cell membrane
signaling protein, responsible for driving the B cell to
differentiate and to go on to antibody secretion (Uckun et
al., 1991). CD40L/CD40 interactions have been reported
to have profound immunological relevance to various
immune responses in a number of studies (Allen et al.,
1993; Durie et al., 1994,1993; Ranheim et al., 1993; Laman
et al., 1996; Gerritse et al., 1996). In our previous exper-
iments, a short course of anti-CD40L mAb therapy, initi-
ated the same day as LP-BM5 infection, was successful
in preventing the establishment of MAIDS-associated
splenomegaly, hypergammaglobulinemia, and immuno-
deficiency, the latter as evidenced by the loss of respon-
siveness to both mitogens and allogeneic CTL reactivity
(Green et al., 1996). The present study assessing these
four parameters of MAIDS in mice preinfected with the
LP-BM5 virus complex, so that disease pathogenesis
was well underway before initiation of long-term therapy
with anti-CD40L mAb, further defines the role of CD40L/
CD40 interactions in MAIDS by examining the kinetics of
this needed interaction and its possible requirement for
the progression of MAIDS.
RESULTS
Virus inoculation and establishment of hyper-IgG2a
and splenomegly before initiation of anti-CD40L mAb
treatment
To determine whether continued CD40L/CD40 interac-
tions are needed for the progression, as well as the
initiation, of LP-BM5 virus-induced MAIDS, highly sus-
ceptible B6 mice were first bled for preinfection sera
samples and then infected on day 1 intraperitoneally (IP)
with LP-BM5 (see Material and Methods). On day 20
(experiments 1, 3, and 4) or 27 (experiment 2), a postin-
fection serum was obtained from each mouse to deter-
mine, by comparative ELISA assays for serum IgG2a
levels (see Materials and Methods), whether there was
clear evidence for hyper-Ig. Elevated serum IgG2a and
IgM levels, in particular, have been reported as early as
3 weeks post LP-BM5 infection due to the polyclonal B
cell activation that occurs in MAIDS (Mosier et al 1985;
Pattengale et al., 1982). To provide a reliable and conve-
nient readout to establish that all experimental mice
were actively exhibiting MAIDS before being entered into
this study, we compared pre- and postinfection IgG2a
values, based on our previous study in which serum IgM
values were less pronounced than IgG2a levels at 3–4
weeks post LP-BM5 infection (Green et al., 1996). In
addition, for each experiment a subset of the infected
mice with elevated IgG2a levels was sacrificed at 3 or 4
weeks post LP-BM5 inoculation. This mouse group pro-
vided a representative indicator for splenomegaly as a
second, independent measure of the establishment of
MAIDS in these LP-BM5-infected mice just prior to the
initiation of either anti-CD40L mAb or control hamster
immunoglobulin (HIg) treatment. Only the individual LP-
BM5-inoculated mice that had a six-fold or greater in-
crease in serum IgG2a (approximately 80% of all mice
infected), and that came from a group of mice displaying
an average increase in spleen weight of at least 50% at
3–4 weeks, were injected IP with either 250 mg of anti-
CD40L mAb or HIg. Treatment was started on day 21
(experiments 1, 3, and 4) or 28 (experiment 2) post LP-
BM5 inoculation. Initially, an injection was given every
other day for four treatments, i.e., a total of 1 mg of
antibody per mouse, and then twice weekly thereafter
until 4 days before sacrifice at day 49 or 56 (experiment
2 and experiments 1, 3, and 4 respectively).
Effect of delayed treatment with anti-CD40L mAb on
the progression of MAIDS
At the 7- or 8-week postinfection time point, drawing
on four separate experiments with similar results, a total
of 15/15 LP-BM5-infected mice, treated with HIg, exhib-
ited clear features of MAIDS. These mice displayed pro-
found splenomegaly (Fig. 1) and dramatically elevated
IgG2a levels (Fig. 2). Also as expected, these HIg-treated
mice were all immunodeficient as measured by their
ability to generate allogeneic CTL (Fig. 3) and their se-
verely depressed responsiveness (,25% of control) to
Con A (Fig. 4), although one HIg-treated mouse dis-
played a somewhat elevated level of Con A responsive-
ness equaling 35% of that of the no-infection, positive
control response group (see legend to Fig. 4). Based on
these results with HIg-treated mice that clearly scored as
disease-positive, we established criteria for these four
readouts of MAIDS. We then used these criteria to as-
sess the anti-CD40L-treated mice and classify them as
either having or not having a substantial degree of dis-
ease (see legends to Figs. 1–4).
Alternatively, of 15 LP-BM5-infected mice treated in
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parallel with anti-CD40L mAb, 9 were positively affected
by treatment. Relative to the HIg-treated or ‘‘unaffected’’
anti-CD40L-treated groups (see below), anti-CD40L ther-
apy was effective in these 9 mice, as evidenced at the
time of sacrifice by their near-normal-sized spleens (Fig.
1), greatly reduced levels of serum IgG2a (Fig. 2), and
greatly enhanced ability to both proliferate in response to
Con A stimulation (Fig. 4) and to generate in vitro, pri-
mary-allo-specific CTL (Fig. 3). Mice were placed in the
‘‘affected’’ group by having substantially less disease on
the basis of at least three of these four criteria. Indeed,
only 2 of the 9 affected mice met only 3 of the 4 param-
eters of lessened disease severity: one mouse failed to
generate allo CTL, and the other had a spleen weight at
the time of sacrifice that slightly exceeded our cutoff
criterion. Another affected mouse met all four parame-
ters but had a ‘‘low normal’’ Con A response of about 38%
of the average no-infection control response.
For the other 6 ‘‘unaffected’’ LP-BM5 infected mice,
which also exhibited clear early features of MAIDS at 3–4
weeks postvirus, treatment with anti-CD40L mAb had
much less, if any, effect on the subsequent progression
of MAIDS. All 6 of these mice exhibited terminal spleen
sizes (Fig. 1), serum IgG2a levels (Fig. 2), and responses
to Con A (Fig. 4) and allo CTL reactivity (Fig. 3) much
more similar to those seen for HIg than for the positively
affected anti-CD40L mAb-treated mice. Thus, each of
these 6 ‘‘unaffected’’ were scored as clearly diseased on
the basis of all four of four criteria for MAIDS.
Determination of antibody production to the
administered anti-CD40L mAb
In an effort to understand why only 60% of the anti-
CD40L-treated mice showed a halt in the progression, if
not a reversal, of MAIDS, we assessed the possibility
that because the mAb is of hamster origin, administered
antibody may have triggered antibody production to anti-
CD40L in the unaffected recipients. End point (7/8 weeks
postinfection) sera were available for only three of the
four separate experiments (12 total mice rather than the
complete set of 15 mice treated with anti-CD40L mAb),
obtained from both affected and unaffected anti-CD40L-
FIG. 2. MAIDS-associated hypergammaglobulinemia. Mean mg/ml 6
standard deviation serum levels for IgG2a are represented for the
indicated time points relative to virus infection. An IgG2a level of # 800
mg/ml at the time of sacrifice was assigned as the cutoff for classifying
LP-BM5-infected, anti-CD40L-treated mice, as mAb therapy/affected. Of
note were the following significant differences (Student’s t test)—for
preinfection serum IgG2a values vs values after LP-BM5 infection but 1
day prior to the initiation of Ab therapy (postinfection, day 21 Ab
therapy): P , 0.0001, LP-BM5, HIg; P 5 0.003, LP-BM5, anti-CD40L/all;
P 5 0.0013, LP-BM5, anti-CD40L/affected; P 5 0.029, LP-BM5, anti-
CD40L nonaffected; for values at the time of sacrifice (terminal): P 5
0.0002, LP-BM5, HIg vs LP-BM5, anti CD40L/affected; and P 5 0.0006,
LPBM5, mAb-affected vs LP-BM5, mAb nonaffected.
FIG. 1. Splenomegaly in LP-BM5-infected mice treated with delayed
anti-CD40L mAb or HIg therapy. B6 mice were infected for 3 weeks
(experiments 1, 3, and 4, see Figs. 3 and 4) or 4 weeks (experiment 2)
with LP-BM5 virus before anti-CD40L mAb or HIg therapy was initiated
as described under Materials and Methods. The first and second bars,
representing mean spleen weight 6 standard deviation, of the nonin-
fected vs LP-BM5-infected/HIg-treated mice were highly statistically
different (P , 0.0001) as evaluated by Student’s t test. Previous exper-
iments and experiment 1 indicated that very similar results were ob-
tained with LP-BM5-infected/HIg-treated vs only LP-BM5-infected mice
as an additional control. A highly significant difference also existed
between the mean spleen weights of the LP-BM5-infected/HIg-treated
mice and the infected, anti-CD40L mAb-treated/affected mice (P ,
0.0001). Of the 15 LP-BM5-infected B6 mice that received delayed
treatment with anti-CD40L mAb, there was also a significant difference
(P 5 0.0045) between the 9 mice that were positively affected (mean
spleen weight 5 132 mg) vs the 6 mice that were not affected by
anti-CD40L mAb treatment (mean spleen weight 5 237 mg). A spleen
weight of #150 mg at the time of sacrifice was assigned as the cutoff
for classifying mice as positively affected by anti-CD40L mAb therapy,
with greater spleen weights indicating full disease for the unaffected
and control infected mice. The numbers of mice in the other groups
were: no infection, 12; and LP-BM5/HIg, 15.
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treated mice, and were assessed for the presence of
antibodies to the anti-CD40L mAb by ELISA (Materials
and Methods). Of these 12 mice, all 5 unaffected mice
had made clearly detectable antibodies to the anti-
CD40L antibody, whereas there was little or no such
activity for the 7 mice that were positively affected by
anti-CD40L mAb therapy (Fig. 5). In view of this exact 1:1
correlation between the effectiveness of anti-CD40L
therapy in interfering with the progression of MAIDS and
lack of substantial production of antibodies to the ham-
ster anti-CD40L antibody, it seemed reasonable that the
failure of therapy in a minority of the mice might be due
to the functional blocking and/or physical removal of the
anti-CD40L mAb.
Among the alternative explanations for the failure of de-
layed anti-CD40LmAb therapy to be effective in all treated
mice, we addressed the possibility that initiation of antibody
treatment at 3/4 weeks postinfection was by chance at a
time when the requirement for CD40L/CD40 interactions
was waning. If this was the case, in some (i.e., about 40%)
of the mice disease would have progressed beyond the
point at which antibody therapy could be effective (see
Discussion). To test this possibility, mice were treated with
anti-CD40L mAb beginning as early postinfection as we
could verify clear MAIDS symptomatology, namely, 2
weeks. In these mice, 4 were positively affected and 3 were
unaffected by anti-CD40L mAb therapy, as determined by
all MAIDS disease criteria (8 week postinfection IgG2a
levels, splenomegaly, and Con A and allo CTL responses).
For example, the mean spleen weight for those mice af-
fected by anti-CD40L mAb therapy was 103 mg vs 280 mg
for anti-CD40L mAb-treated but unaffected mice or 353 mg
for HIg-treated mice. Each of the 4 affected mice had little
or no antibodies to anti-CD40L mAb, whereas all 3 unaf-
fected mice produced substantial levels of anti-anti-CD40L
mAb serum activity. Thus with respect to the 60% success
rate of anti-CD40L therapy, these data did not support an
explanation based on the required CD40L/CD40 interac-
tions lasting through only 3–4 weeks postinfection. At the
other kinetic extreme, however, our preliminary results with
LP-BM5-infected B6 mice in which anti-CD40L mAb was
initially administered at 9, 15, or 18 weeks postinfection
indicated that there was not a continuing role for CD40L/
CD40 interactions at these later stages of MAIDS. All mice
in this study uniformly exhibited clear MAIDS symptomatol-
ogy based on the MAIDS disease criteria of splenomegaly,
Con A, and allo CTL responses as measured at the termi-
FIG. 4. Con A responsiveness in LP-BM5-infected B6 mice. Mice were
infected with LP-BM5 virus (see legend, Fig. 1) and anti-CD40L mAb
therapy was initiated as described under Materials and Methods. Mice
were sacrificed (see legend Fig. 3) and spleen cell cultures were set up as
described under Materials and Methods. Data points are for responses by
individual mice calculated as a percentage of the mean Con A response
obtained from spleen cells from a group of noninfected positive control
mice included in each experiment. The raw/nonnormalized positive control
delta cpm were 211,626, 99,557, 152,139, and 85,498, respectively, for
experiments 1–4. We assigned a value of . 35% of the no-infection
positive control response as the cutoff for determining whether the LP-
BM5-infected, anti-CD40L-treated mice were affected by mAb therapy. Of
note were the following significant differences based on the mean values
for the three treatment groups represented by the indicated straight line:
P 5 0.0001, LP-BM5-infected/HIg-treated mice vs LP-BM5-infected, anti-
CD40L mAb-affected mice; and P , 0.0001, LP-BM5-infected, mAb-af-
fected vs mAb-nonaffected mice.
FIG. 3. Allogeneic CTL generation in LP-BM5-infected mice treated
with delayed anti-CD40L mAb or HIg therapy. B6 mice were infected
with LP-BM5 virus (see legend, Fig. 1) before anti-CD40L mAb or HIg
therapy was initiated as described under Materials and Methods. At 7
(experiment 2) or 8 weeks (experiments 1, 3, and 4) post virus infection,
mice were sacrificed and spleen cell cultures were set up as described
under Materials and Methods. Presented data points are for responses
obtained from an E:T ratio of 100:1 for individual experimental mice,
calculated as a percentage of the mean positive control allo CTL
response from a group of noninfected control mice included in each
experiment). The raw/nonnormalized noninfection positive control lysis
values for experiments 1–4 were 63, 71, 74, and 47%, respectively. The
values for target cell spontaneous release were # 19%. A value of .
35% of the noinfection positive control response was assigned as the
cutoff for determining whether the LP-BM5-infected, anti-CD40L-treated
mice were affected by mAb therapy. Of note were the following signif-
icant differences based on the mean values for the three treatment
groups represented by the indicated straight line: P 5 0.0002, LP-BM5-
infected/HIg-treated mice vs LP-BM5-infected, anti-CD40L-affected
mice; and P 5 0.0006, mAb-affected vs mAb-nonaffected mice.
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nation of 4 weeks of anti-CD40L mAb therapy. For example,
the infected mice treated with anti-CD40L mAb had a mean
allo CTL response equal to only about 18% of that of the
positive control (age-matched normal mice) response vs
19% of the control response for infected mice treated with
HIg. In these mice, which uniformly failed mAb therapy, it is
important to note that antibodies to the anti-CD40L mAb
were produced sporadically in only half of the mice, arguing
against anti-anti-CD40L Ab formation as the essential
cause of the uniform failure of this very delayed therapy.
DISCUSSION
Delayed anti-CD40L mAb treatment of B6 mice infected
3/4 weeks previously with LP-BM5 virus was thus effective
in inhibiting the progression of MAIDS in 60% of the mice,
based on reduced splenomegaly (Fig. 1), lower serum
IgG2a levels (Fig. 2), and enhanced ability to respond to
Con A (Fig. 4) and to generate allo CTL responses (Fig. 3)
at 7/8 weeks postinfection. These decreased parameters of
MAIDS were in contrast to the severe disease exhibited by
both the other 40% of anti-CD40L treated mice that were not
affected and those mice treated with control Ab. These
results clearly indicated that there is a continuing require-
ment for CD40L/CD40 interactions in the progression of
MAIDS. Although the precise reason for this requirement is
unknown, it does not appear to relate to an inhibition of the
expression of the causative defective retrovirus. In initial
experiments, a semiquantitative RT–PCR assessment of
defective gag mRNA expression failed to indicate consis-
tent, substantial differences in the viral burden of LP-BM5-
infected mice that had been given delayed therapy with HIg
or anti-CD40L, in the latter case whether belonging to the
mAb-affected or unaffected groups (data not shown). This
finding was not surprising, given that we had previously
shown no meaningful differences in viral load when anti-
CD40L therapy was initiated immediately postinfection and
shown to inhibit the initiation of MAIDS (Green et al., 1996).
The reason for only a 60% rate of effectiveness of the
anti-CD40L therapy was not high intrinsic mouse-to-
mouse variation in susceptibility to MAIDS. First, B6 mice
are highly sensitive to LP-BM5-induced disease. Second,
all LP-BM5-infected B6 mice, before entry into this study,
were required to have at least a six-fold increase (rela-
tive to the preinfection baseline) in serum IgG2a 1 day
prior to the initiation of anti-CD40L mAb or HIg therapy
and were further equally divided into anti-CD40L mAb or
HIg-treated groups, based on the specific serum IgG2a
values. In particular, the anti-CD40L-treated mice that
were unaffected by this therapy and went on to develop
full-blown MAIDS did not do so because they had more
severe early disease (hyper Ig) just before the initiation
of mAb therapy. Third, although there was some mouse
to mouse variation at 7/8 weeks post LP-BM5 infection in
the exact levels of spleen size, hyper-Ig, and Con A and
allo CTL responses, statistically significant differences
for all of these MAIDS disease parameters were ob-
served in comparisons between the anti-CD40L mAb-
affected mouse group vs HIg-treated control mice (Figs.
1–4). For the two anti-CD40L mAb treated mice which
were placed into the affected group based on their re-
sults for 3/4, not 4/4, disease parameters, there was no
evidence from these three readouts to suggest that these
two mice were more diseased than the other seven
affected mice.
One explanation for the ineffectiveness of anti-CD40L
therapy in 40% of the mice was the formation of antibod-
ies to the hamster anti-CD40L mAb: none of the seven
treated mice that responded to therapy made substantial
levels of antibodies to anti-CD40L mAb, whereas all five
mice that failed to respond favorably to therapy produced
FIG. 5. The generation of anti-anti-CD40L mAb antibodies. Mice were
infected with LP-BM5 virus and 3 weeks later (experiments 3 and 4) or 4
weeks later (experiment 2) were started on anti-CD40L mAb therapy as
described under Materials and Methods. Available sera from anti-CD40L
mAb-treated, 7-week (experiment 2) and 8-week (experiments 3 and 4)
LP-BM5-infected mice (n 5 12) were screened for the presence of anti-
bodies to the anti-CD40L mAb by ELISA assay: mice not affected by
anti-CD40L mAb therapy (n 5 5, dark triangles) affected by anti-CD40L
therapy (n 5 7, open circles). The following criteria were used to grade the
antibody response based on OD readings: .0.05, 1; 0.006–0.05, 6;
,0.006 (the OD reading for noninfected negative control sera), 2. The 7
anti-CD40L-treated/affected mice that produced 6 or no anti-anti-CD40L
antibodies also made 6 or no antibodies reactive with HIg, whereas the
5 nonaffected mice that made anti-anti-CD40L antibodies also had anti-
body activity to HIg, and the HIg-treated mice (n 5 9) all made anti-HIg
antibodies that also reacted with anti-CD40L (data not shown).
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a strong antibody response to anti-CD40L mAb (Fig. 5).
Similar findings of only partially effective anti-CD40L
mAb therapy have also been recently reported in a study
involving long-term treatment of (NZB 3 NZW)F1 mice
(Early et al., 1996). At 10 months about 60% of the anti-
CD40L-treated mice in this model of spontaneous SLE
were alive and were essentially free of antibodies to the
anti-CD40L mAb, whereas the 40% that died of lupus
were positive for anti-CD40L antibodies. The precise
mechanism(s) by which antibodies to anti-CD40L mAb
apparently inhibit its action is unknown, but may range
from simple binding and inactivation to immune complex
formation and subsequent removal. It is important to
note, however, that, unlike this model of SLE where
immune complex deposition is integral to the disease,
there was no evidence that immune complexes exacer-
bate MAIDS. Thus, most HIg-treated mice produced
measurable levels of anti-HIg antibodies, yet these mice
had no greater disease than those infected mice that
failed to make anti-HIg antibodies or that did not receive
HIg (Green et al., 1996).
Also in contrast to the (NZB 3 NZW)F1 study where the
authors suggested that the development of antibodies to
the anti-CD40L mAb might be due in part to the propen-
sity of this F1 to develop a variety of autoantibodies (Early
et al., 1996), antibody formation to anti-CD40L mAb
seems somewhat paradoxical in MAIDS. That is, in the
very mice in which anti-CD40L mAb therapy failed and
MAIDS progressed with its attendant immunodeficiency
a strong antibody response to the anti-CD40L mAb de-
veloped. Perhaps the large total dosage (2 mg) of anti-
CD40L mAb was sufficient to generate an antibody re-
sponse which was not ablated by LP-BM5-associated
immunodeficiency—clearly there are many examples
from other systems where low/nonresponsiveness is
overcome by high antigen dose. Why only about 40% of
the anti-CD40L mAb-treated mice developed anti-anti-
bodies and failed therapy is unclear, but may affect a
stochastic process. The fact that the anti-CD40L mAb-
affected, immunocompetent mice did not make substan-
tial levels of anti-anti-CD40L antibodies, however, sug-
gests that, whatever the initiating factor(s), the continued
development of MAIDS in the unaffected anti-CD40L
mAb-treated mice might have contributed to the anti-
antibody response. The continued B cell activation, ger-
minal center formation, and hyper-Ig of such mice would
be likely contributing factors.
An alternative possibility for why delayed anti-CD40L
mAb treatment of LP-BM5-infected mice was only 60%
effective could be based on the kinetics of the require-
ment for CD40L/CD40 interactions in MAIDS. Our previ-
ous studies showed that between days 1 and 7 post
LP-BM5 infection, CD40L/CD40 interactions are critical
for MAIDS initiation (Green et al., 1996). If requirement for
CD40L/CD40 interactions starts to wane at about 3/4
weeks post LP-BM5 infection, in a random manner, some
mice would be beyond the CD40L/CD40 requirement
‘‘window’’ when delayed treatment was initiated here,
while others would not. If this was the case, a percent-
age of mice greater than 60% would be positively af-
fected if therapy was started earlier postinfection. To
address this possibility, mAb therapy was initiated at 2
weeks, the earliest time post virus infection in which a
cohort of mice could be clearly classified as having
MAIDS, based on hyper-Ig levels. Again 60% (4/7) of the
LP-BM5-infected mice treated with anti-CD40L mAb ther-
apy were positively affected and exhibited much less
severe MAIDS, and only unaffected mice made substan-
tial levels of antibodies to the anti-CD40L mAb. Thus,
these data were consistent with anti-antibody production
as the basis for failure of therapy and a continuing
requirement for CD40L/CD40 interactions for MAIDS
through at least week 4 postinfection.
It is also important to consider in the affected mice
whether the progression of MAIDS was simply halted or
whether there was an actual reversal of disease, but to
differentiate between these possibilities the various dis-
ease parameters need to be considered separately. We
observed a clear decrease in the extent of hyper-IgG2a
development in the mAb-affected group when comparing
mean IgG2a values post LP-BM5 infection, at 1 day
before Ab therapy, vs at the terminal 7/8 weeks postin-
fection (Fig. 2). Two of the nine mice in the mAb-affected
group exhibited no increase at the terminal time point
above that of their 3-week postinfection IgG2a level. The
life span of plasma cells and B cells already committed
to Ig production, and the extended serum half-life of
IgG2a, as accumulative aspects of IgG2a serum levels
prior to initiation of delayed anti-CD40L mAb therapy,
however, may have masked an actual decreased devel-
opment or reversal of hypergammaglobulinemia. We did
obtain evidence in this study, by immunohistochemical
evaluation of splenic sections, that delayed anti-CD40L
mAb treatment of LP-BM5-infected mice reverses the
related MAIDS parameters of B cell activation and ger-
minal center formation (data not shown). Mice infected
14 days earlier with LP-BM5 virus were compared to
parallel infected mice that then received a course of
anti-CD40L mAb therapy from days 14 to 21. Extensive
germinal centers consisting of peanut agglutinin-binding
activated B cells (Butcher et al 1982; Coico et al., 1983;
Foy et al., 1994; Nieuwenhuis et al., 1992; Rose et al.,
1980) were readily detected at day 14 postinfection in
untreated or day 14–21 HIg-treated control mice. In con-
trast, only fragments of germinal centers were observed
at day 21 in splenic sections obtained from the mice
receiving delayed anti-CD40L treatment. These data ex-
tend our previous findings that anti-CD40L mAb therapy,
initiated the same day as LP-BM5 infection, prevents the
initial development of MAIDS-associated germinal cen-
ters (Green et al., 1996). Reversal of germinal centers by
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delayed anti-CD40L mAb therapy in a non-MAIDS sys-
tem has also been described (Han et al., 1995).
Our data on extent of splenomegaly also support an
effect of anti-CD40L mAb that was more than a halt in
MAIDS progression. At 3/4 weeks post LP-BM5 infection
(prior to mAb therapy) the mean spleen weight of the
control group was 168 mg versus 132 mg at 7/8 weeks
postvirus for the anti-CD40L mAb-affected group (P 5
0.016). The mean spleen weight at 7–8 weeks for HIg-
treated mice was 305 mg, a highly statistically significant
difference compared to the terminal spleen weight for
mAb-treated, affected mice (P , 0.0001). Because we
(Green et al., 1996, 1994) and others (Cerny et al., 1990;
Morse et al., 1989) have observed that substantial inhi-
bition of mitogen reactivity and allo CTL generation oc-
curs later than 3/4 weeks post LP-BM5 infection, whether
the mAb therapy reversed or just slowed MAIDS progres-
sion could not be addressed based on these two param-
eters. Of note, delayed anti-CD40L mAb therapy was
beneficial in 60–70% of SJL/J mice with induced experi-
mental allergic encephalomyelitis (Gerritse et al., 1996).
To avoid the development of anti-anti-CD40L antibod-
ies encountered in this study, a ‘‘mouse version’’ of the
hamster anti-CD40L mAb could possibly be very effec-
tive in delayed treatment of LP-BM5-infected mice, anal-
ogous to the various humanized murine mAbs that have
been developed for clinical use. Regardless of the value
of anti-CD40L mAb as an effective therapy per se, how-
ever, the present data clearly indicate the importance of
CD40L/CD40 interactions in the progression, as well as
the initiation (Green et al., 1996), of MAIDS. By extension,
since at least some aspects of AIDS, in particular B cell
activation, hyper-Ig production, immunodeficiency, and
terminal B cell lymphoma formation, parallel MAIDS, our
results may be of importance to HIV-caused disease.
Although the evidence for involvement of CD40L/CD40
interactions in AIDS is limited, there are at least two
studies of particular note. First, Gras et al. (1996) have
reported that triggering through CD40 enhances postin-
fection HIV replication in B cells in vitro. Second, Pinchuk
et al. (1994) have reported data which suggest that
CD40L/CD40 interactions between dendritic cells (DC)
and T cells may be linked to transmission of HIV from DC
to T cells and infection of the latter in vivo. Confirmation
of these results and additional studies will be required to
determine if CD40L/CD40 interactions are a common
requirement for retrovirus-induced immunodeficiency.
MATERIALS AND METHODS
Mice
Seven-week-old male C57BL/6 mice were purchased
from the National Institutes of Health (Bethesda, MD).
They were housed in the Dartmouth Medical School
Animal facility and were used when 8–10 weeks of age.
Cell lines
LB27.4, a murine B cell hybridoma (H-2b,d), and P815, a
murine mastocytoma (H-2d), were maintained in RPMI
1640 with 5% FBS, L-glutamine, antibiotics, and 2-Me
(Life Technologies, Inc., Grand Island, NY) Both lines
were grown at 37°C with 5% CO2.
Inoculation reagents
LP-BM5 virus was prepared in our lab as described in
Klinken et al. (1988). G6 cells, originally provided to us by
Drs. Janet Hartley and Herbert Morse, as a cloned cell
line from SC-1 cells infected with the LP-BM5 virus mix-
ture, were cocultured with uninfected SC-1 cells. Mice
were infected intraperitoneally with 0.25 ml of a virus
stock that was quantitated by an XC plaque assay (Rowe
et al., 1970) to contain approximately 7 3 105 ecotropic
plaque-forming units/ml. Anti-CD40L monoclonal anti-
body was purified by ion-exchange HPLC from ascites
obtained from hamsters inoculated with MR1 hybridoma
cells. MR1 was subcloned from a hybridoma population
that was obtained after immunizing hamsters with acti-
vated Th1 (D1.6) cells, the latter originally supplied by
David Parker (University of Massachusetts, Worcester),
with subsequent splenocyte fusion to NS1 mouse my-
eloma cells (Noelle et al., 1992).
Serum immunoglobulin, antibodies to anti-CD40L
mAb, and ELISA determinations
For measuring hypergammaglobulinemia, affinity-puri-
fied goat anti-mouse IgG2a antibody (Southern Biotech-
nology Assoc., Birmingham, AL) was diluted to 7 mg/ml in
PBS to coat 96-well ELISA grade plates (Becton–Dickin-
son, Oxford, CA) overnight at 4°C. The plates were then
washed three times with PBS and blocked for 1 h with 5%
BSA/PBS (Sigma, St Louis, MO) at 37°C. Preimmune
serum (100 ml) or sera obtained 3 and 8 weeks post virus
inoculation were then plated and allowed to incubate for
2 h at 37°C. The plates were then washed three time
with PBS and alkaline phosphatase-labeled goat anti-
mouse immunoglobulin (Southern Biotechnology Assoc.)
was then added. After a 2-h, 37°C incubation, p-nitrophe-
nyl phosphate (Sigma Chemical) provided a colorimetric
change which was then quantitated at 405 nm by an
ELISA reader (Dynatech Laboratories, Inc., Alexandria,
VA). For measuring levels of anti-HIg or antibodies to
anti-CD40L, HIg or anti-CD40L antibody was plated at 10
mg/ml diluted in 0.1 M sodium carbonate/bicarbonate
buffer and the rest of the ELISA was conducted as
described above.
Spleen cell response to mitogens
Spleen cells (4 3 105) from individual normal and
experimental mice were plated in triplicate into 96-well
plates with media containing 5% FBS, L-glutamine, anti-
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biotics, and a final concentration of 2 mg/ml Con A. After
72 h all wells were terminally pulsed with 1 mCi [3H]thy-
midine (Dupont NEN, Boston, MA) and harvested 6 h
later (Skatron, Lier, Norway) for assessment of thymidine
incorporation by scintillation counting (TM Analytic,
Brandon, FL).
Generation of allogeneic CTL
Responder splenocytes (1 3 107) from inoculated or
normal B6 mice were mixed with irradiated (8000 rad)
LB27.4 tumor cells at a responder to stimulator ratio of
35:1. These cell mixtures were cultured in RPMI 1640, 5%
FBS, penicillin, streptomycin, and L-glutamine for 6 days
at 37°C in 5% CO2 before being harvested for use as
effector cells.
51Chromium release assays
P815 target cells were resuspended in 100 ml FBS and
labeled with 100 ml sodium chromate (2 mCi/ml, NEN-
Dupont). After washing, target cells (5 3 103) were plated
into duplicate V-shaped wells with varying numbers of
effector cells to achieve effector to target ratios of 100:1,
20:1, and 4:1. The plates were centrifuged briefly and
incubated at 37°C in 5% CO2 for 4 h. Cell-free superna-
tant (100 ml) were collected for counting on a gamma
counter (Wallac, LKB, Gaithersburg, MD). All wells were
plated in duplicate with the percent specific lysis values
ranging 6 10% of the mean value. Percent specific lysis
was defined as [(a 2 b)/c] 3 100, where a 5 experimen-
tal cpm released, b 5 spontaneous cpm released, and
c 5 freeze–thaw releasable (about 80% of total) cpm. The
values for spontaneous target cell release were 19% or
lower.
Immunohistochemistry
B6 mice were infected with 0.25 ml of LP-BM5 virus on
day 1. On day 13 splenic sections were fixed with ace-
tone, incubated with peanut agglutinin–biotin followed by
avidin–horseradish peroxidase, and stained with diami-
nobenzidine (Sigma) as described previously (Green et
al., 1996). After germinal centers were found in splenic
sections from control 13 day-infected LP-BM5 mice, 250
mg of either anti-CD40L mAb or HIg was given every
other day for a total of 1 mg to 14-day LP-BM5-infected
mice. On day 21 postvirus tissue sections were obtained
from both the anti-CD40L mAb or HIg-treated mice and
stained as described above.
ACKNOWLEDGMENTS
We thank Herbert C. Morse and Janet Hartley for kindly providing the
original stock for the G6 cell, Dr. Christopher Burns for his gift of
reagents and advice on the ELISA assays for anti-antibody production,
Jason Gigley for the purification of anti-CD40L antibody, and Arjan
Schoneveld for immunohistochemical assistance. We also are appre-
ciative of Hillary White, Victor Kim, Shawn Marie Mayrand, Robert Rich,
and Roza Sypniewska for their helpful discussions.
REFERENCES
Allen, R.C., Armitage, R. J., Conley, M. E., Rosenblatt, H., Jenkins, N. A.,
Copeland, N. G., Bedell, M. A., Edelhoff, S., Disteche, J., and Simo-
neaux, D. K. (1993). CD40 ligand gene defects responsible for X-
linked hyper-IgM syndrome. Science 259, 990.
Armitage, R. J., Fanslow, W. C., Strockbine, L., Sato, T. A., Clifford, K. N.,
Madcuff, B. M., Anderson, D. M., Gimpel, S. D., Davis-Smith, T.,
Maliszewski, C. R., Clark, E. A., Smith, C. A., Grabstein, K. H., Cos-
man, D., and Spriggs, M. K. (1992). Molecular and biological charac-
terization of a murine ligand for CD40. Nature 357, 80.
Aziz, D. C., Hanna, Z., and Jolicoeur, P. (19889). Severe immunodefi-
ciency disease induced by a defective murine leukemia virus. Nature
(London) 338, 505.
Buller, R. M. L., Yetter, R. A., Fredrickson, T. N., and Morse, H.C., III
(1987). Abrogation of resistance to severe mousepox in C57BL/6
mice infected with LP-BM5 murine leukemia viruses. J. Virol. 61, 383.
Butcher, E. C., Rouse, R. V., Coffman, R. L., Nottenberg, C. N., Hardy,
R. R., and Weissman, I. (1982). Surface phenotype of Peyer’s patch
germinal center cells: Implications for the role of germinal centers in
B cell differentiation. J. Immunol. 129, 2698.
Cerny, A., Hugin, A. W., Hardy, R. R., Hayakawa, K., Zinkernagel, R. M.,
Makino, M., and Morse, H. C., III (1990). B cells are required for
induction of T cell abnormalities in a murine retrovirus-induced
immunodeficiency syndrome. J. Exp. Med. 171, 315.
Chattopadhyay, S. K., Morse, H.C., III, Makino, M., Ruscetti, S. K., and
Hartley, J. W. (1989). A defective virus is associated with induction of
a murine retrovirus-induced immunodeficiency syndrome, MAIDS.
Proc. Natl. Acad. Sci. USA 86, 3862.
Coico, R. F., Bhogal, B. S., and Thorbecke, G. J. (1983). Relationship of
germinal centers in lymphoid tissue to immunologic memory. VI.
Transfer of B cell memory with lymph node cells fractionated accord-
ing to their receptors for peanut agglutinin. J. Immunol. 131, 2254.
Durie, F. H., Fava, R. A., Foy, T. M., Aruffo, A., Ledbetter, J. A., and Noelle,
R. J. (1993). Prevention of collagen-induced arthritis with an antibody
to gp39, the ligand for CD40. Science 261, 1328.
Durie, F. H., Foy, T. M., and Noelle, R. J. (1994). The role of CD40 and its
ligand (gp39) in peripheral and central T cell tolerance and its
contribution to autoimmune disease. Res. Immunol. 45, 163.
Early, G. S., Zhao, W., and Burns, C. M. (1996). Anti-CD40 ligand anti-
body treatment prevents the development of lupus-like nephritis in a
subset of New Zealand black x New Zealand white mice. J. Immunol.
157, 3159.
Foy, T. M., Laman, J. D., Ledbetter, J. A., Aruffo, A., Claassen, E., and
Noelle, R. J. (1994). Gp39-CD40 interactions are essential for germi-
nal center formation and the development of B cell memory. J. Exp.
Med. 180, 157.
Gerritse, K., Laman, J. D., Noelle, R. J., Aruffo, A., Ledbetter, J. A.,
Boersma, W. J. A., and Claassen, E. (1996). CD40-CD40 ligand inter-
actions in experimental allergic encephalomyelitis and multiple scle-
rosis. Proc. Natl. Acad. Sci. USA 93, 2499.
Giese, N. A., Giese, T., and Morse, H. C., III (1994). Murine AIDS is an
antigen-driven disease: Requirements for major histocompatibility
complex class II expression and CD41 T cells. J. Virol. 68, 5819.
Gras, G, Legendre, C., Krzysiek, R., Dormont, D., Galanaud, P., and
Richard, Y. (1996). CD40/CD40L interactions and cytokines regulate
HIV replication in B cells in vitro. Virology 220, 309.
Green, K. A., Crassi, K. M., Laman, J. D., Schoneveld, A., Strawbridge,
R. R., Foy, T. M., Noelle, R. J., and Green, W. R. (1996). Antibody to the
Ligand for CD40 (gp39) inhibits murine AIDS-associated splenomeg-
aly, hypergammaglobulinemia, and immunodeficiency in disease-
susceptible C57BL/6 mice. J. Virol. 70, 2569.
Green, W. R., Green, K. A., and Crassi, K. M. (1994). Adoptive transfer of
polyclonal and cloned cytolytic T lymphocytes (CTL) specific for
mouse AIDS-associated tumors is effective in preserving CTL re-
267CD40L/CD40 INTERACTIONS IN MURINE AIDS
sponses: A measure of protection against LP-BM5 retrovirus-in-
duced immunodeficiency. J. Virol. 68, 4679.
Han, S., Hathcock, K., Zheng, B., Kepler, T. B., Hodes, R., and Kelsoe, G.
(1995). Cellular interaction in germinal centers, Roles of CD40 ligand
and B7-2 in established germinal centers. J. Immunol. 155, 556.
Hartley, J. W., Fredrickson, T. N., Yetter, R. A., Makino, M., and Morse,
H. C., III (1989). Retrovirus-induced murine acquired immunodefi-
ciency syndrome: Natural history of infection and differing suscepti-
bility of inbred mouse strains. J. Virol. 63, 1223.
Huang, M., Simard, C., and Jolicoeur, P. (1989). Immunodeficiency and
clonal growth of target cells induced by helper-free defective retro-
virus. Science 246, 1614.
Huang, M., Simard, C., Kay, D. G., and Jolicoeur, P. (1991). The majority
of cells infected with the defective murine AIDS virus belong to the
B-cell lineage. J. Virol. 65, 6562.
Huang, M., Takac, M., Kozak, C., and Jolicoeur, P. (1995). The murine
AIDS defective provirus acts as an insertional mutagen in its infected
target B cells. J. Virol. 69, 4069.
Jolicoeur, J. P. (1991). Murine acquired immunodeficiency syndrome
(MAIDS): An animal model to study AIDS pathogenesis. FASEB 5,
2398.
Kim, W. K., Tang, Y., Kenny, J. J., Longo, D. L., and Morse, H. C. III (1994).
In murine AIDS, B cells are early targets of defective virus and are
required for efficient infection and expression of defective virus in T
cells and macrophages. J. Virol. 68, 6767.
Klinken, S. P., Fredrickson, T. N., Hartley, J. W., Yetter, R. A., and Morse,
H.C., III (1988). Evolution of B cell lineage lymphomas in mice with a
retrovirus-induced immunodeficiency syndrome, MAIDS. J. Immunol.
140, 1123.
Klinman, D. M., and Morse, H. C., III (1989). Characteristics of B cell
proliferation and activation in murine AIDS. J. Immunol. 142, 1144.
Kubo, Y., Kakimi, K., Higo, K., Kobayashi, H., Ono, T., Iwama, Y., Kuriba-
yashi, K., Hiai, H., Adachi, A., and Ishimoto, A. (1996). Possible origin
of murine AIDS (MAIDS) virus: Conversion of an endogenous retro-
viral p12 gag sequence to a MAIDS-inducing sequence by frameshift
mutations. J. Virol. 70, 6405.
Laman, J. D., Claassen, E., and Noelle, R. J. (1996). Functions of CD40
and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 16, 59.
Legrand, E., Daculsi, R., and Duplan, J. F. (1981). Characteristics of the
cell populations involved in extrathymic lymphosarcoma induced in
C57BL/6 mice by RadLV-RS. Leukemia Res. 5, 223.
Morse, H. C., III, Chattopadhyay, S. K., Makino, M., Fredrickson, T. N.,
Ambros, H. W., and Hartley, J. W. (1992). Retrovirus-induced immuno-
deficiency in the mouse: MAIDS as a model for AIDS. AIDS 6, 607.
Morse, H. C., III, Yetter, R. A., Via, C. S., Hardy, R. R., Cerny, A.,
Hayakawa, K., Hugin, A. W., Miller, M. W., Homes, K. L., and Shearer,
G. M. (1989). Functional and phenotypic alterations in T cell subsets
during the course of MAIDS, a murine retrovirus-induced immuno-
deficiency syndrome. J. Immunol. 143 844.
Mosier, D. E., Yetter R. A., and Morse, H. C., III (1987). Functional T
lymphocytes are required for a murine retrovirus-induced immuno-
deficiency disease (MAIDS). J. Exp. Med. 165, 1737.
Mosier, D. E., Yetter, R. A., and Morse, H. C., III (1985). Retroviral
induction of acute lymphoproliferative disease and profound immu-
nosuppression in adult C57BL/6 mice. J. Exp. Med. 161, 766.
Nieuwenhuis, P., Kroese, F. G. M., Opstelten, D., and Seijen, H. G.
(1992). De novo germinal center formation. Immunol. Rev. 126, 77.
Noelle, R. J., Roy, M., Shepherd, D. M., Stamenkovic, I., Ledbetter, J. A.,
and Aruffo, A. (1992). A novel ligand on activated T helper cells binds
CD40 and transduces the signal for the cognate activation of B cells.
Proc. Natl. Acad. Sci. USA 89, 6550.
Pattengale, P. K., Taylor, C. R., Twomey, P., Hill, S., Jonasson, J., Beard-
sley, T., and Haas, M. (1982). Immunopathology of B cell lymphomas
induced in C57BL/6 mice by dualtropic murine leukemia virus
(MuLV). Am. J. Pathol. 107, 362.
Pinchuk, L. M., Polacino, P. S., Agy, M. B., Klaus, S. J., and Clark, E. A.
(1994). The role of CD40 and CD80 accessory cell molecules in
dendritic cell-dependent HIV-1 infection. Immunity 1, 317.
Ranheim, E. A., and Kipps, T. J. (1993). Activated T cells induce expres-
sion of B7/BB1 on normal or leukemic B cells through a CD40-
dependent signal. J. Exp. Med. 177, 925.
Rose, M. L., Birbeck, M. S. C., Wallis, V. J., Forrester, J. A., and Davies,
A. J. S. (1980). Peanut lectin binding properties of germinal centres of
mouse lymphoid tissue. Nature 284, 364.
Rowe, W. P., Pugh, W. E., and Hartley, J. W. (1970). Plaque assay
techniques for murine leukemia viruses. Virology 42, 1136.
Uckun, F. M., Schieven, G. L., Dibirdik, I., Chandan, L. M., Tuel, A. L., and
Ledbetter, J. A. (1991). Stimulation of protein tyrosine phosphoryla-
tion, phosphoinositide turnover, and multiple previously unidentified
serine/threonine-specific protein kinases by the pan-B-cell receptor
CD40/Bp50 at discrete developmental stages of human B-cell ontog-
eny. J. Biol. Chem. 266, 17478.
Yetter, R. A., Buller, R. M. L., Lee, J. S., Elkins, K. L., Mosier, D. E.,
Fredrickson, T. N., and Morse, H.C., III (1988). CD41 T cells are
required for development of a murine retrovirus-induced immunode-
ficiency syndrome (MAIDS). J. Exp. Med. 168, 623.
268 GREEN, NOELLE, AND GREEN
